Sorrento Therapeutics News Releases http://investors.sorrentotherapeutics.com/ Sorrento Therapeutics News Releases en Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-updates-positive-results-phase-1b Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group). Most adverse events associated with RTX administration were expected and included pain, hypertension and Wed, 19 Jun 2019 07:00:00 -0400 Sorrento Therapeutics News Releases 10676 Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-provides-updates-cd38-immunotherapies-and “CD38 Therapeutics” Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic considerations ○ Clinical “Proof-of-Concept” CD38 CAR-T Phase 1 trial progressing and to be concluded in 2019 ○ Next-Gen Wed, 19 Jun 2019 07:00:00 -0400 Sorrento Therapeutics News Releases 10671 Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY) http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-present-jmp-securities-life-sciences SAN DIEGO , June 14, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces today that senior management will be presenting in the upcoming JMP Life Sciences Conference in New York City . Sorrento Therapeutics Speaker: Dr. Fri, 14 Jun 2019 07:00:00 -0400 Sorrento Therapeutics News Releases 10651 Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-explore-potential-initial-public-offering-scilex SAN DIEGO , June 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its majority-owned subsidiary, Scilex Holding Company . No decisions have been taken at this point on the Wed, 12 Jun 2019 07:00:00 -0400 Sorrento Therapeutics News Releases 10641 Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain http://investors.sorrentotherapeutics.com/news-releases/news-release-details/positive-feline-clinical-trial-outcome-motivates-sorrento SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of Mon, 10 Jun 2019 07:00:00 -0400 Sorrento Therapeutics News Releases 10631 Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration http://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-announces-strong-ztlido-sales-growth-after ZTlido ® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in May SP-102 pivotal phase 3 trial remains on track for completion in H1 2020 ZTlido ® 5.4% (3 X strength) trial to be initiated in 2019 for lower back pain indication SAN DIEGO , June 05, Wed, 05 Jun 2019 07:00:00 -0400 Sorrento Therapeutics News Releases 10621 Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-cannabidiol-cbd-global-joint-ventures-and SAN DIEGO , June 04, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd. (“Shenzhen Yunma”), with LifeTech Scientific Co., Ltd. (LifeTech, HKSE: 1302) to commercialize Sorrento’s Tue, 04 Jun 2019 07:00:00 -0400 Sorrento Therapeutics News Releases 10611 Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca). http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-present-20th-annual-b-riley-fbr-investor SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji , Chairman and CEO, will be participating in the upcoming FB Riley Investor Conference and meeting with individual investors. Tue, 21 May 2019 18:25:00 -0400 Sorrento Therapeutics News Releases 10606 Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-establishes-business-unit-address-market-opportunity Cannabidiol (CBD) material from virtually THC-free ( Tue, 16 Apr 2019 09:00:00 -0400 Sorrento Therapeutics News Releases 10506 Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-expands-resiniferatoxin-rtx-clinical SAN DIEGO , April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and Mon, 15 Apr 2019 04:00:00 -0400 Sorrento Therapeutics News Releases 10491